Vitamin D analog paricalcitol may help treat pancreatic cancer
Researchers at the Salk Institute and Dana-Farber Cancer Institute report that a vitamin D analog called paricalcitol could make metastatic pancreatic tumors more vulnerable to chemotherapy in a small clinical trial published on October 3, 2026.
Study design and patient group
The trial tested standard chemotherapy alone or combined with paricalcitol in patients with previously untreated metastatic pancreatic cancer. Participants received the drug either by mouth or through an intravenous route while undergoing treatment.
Safety and tumor response
Researchers found that combining the vitamin D analog with chemotherapy was safe overall for the participants involved in the study. The treatment reduced the activation of fibroblasts within the tumor microenvironment, which may alter the protective environment surrounding the tumors.
Results linked to receptors
Encouraging responses were observed particularly in patients whose tumors showed high levels of the vitamin D receptor. These findings suggest the drug could help break down defenses that currently shield pancreatic cancer from existing therapies.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.